Hindustan Bio Sciences

What Hindustan Bio Sciences does

Hindustan Bio Sciences Limited (HBSL) is an Indian publicly listed pharmaceutical manufacturer (BSE: HBSL, ISIN INE597C01021) incorporated in 2000 and headquartered in Banjara Hills, Hyderabad, with a regional sales office in Bangalore. The company operates world-class manufacturing facilities for finished dosage forms — dry and liquid injectables, liquid and dry syrups, Eye/Ear/Nasal drops, pre-filled syringes, non-sterile and sterile ointments, tablets, and capsules — with approvals from multiple regulatory authorities supporting distribution to healthcare professionals and patients globally. In 2007 the company obtained a Genetic Engineering Approval Committee (GEAC) import license for Recombinant Human Erythropoietin, a niche nephrology drug, which it markets extensively after conducting clinical trials.

The company sells its products via direct distribution to healthcare professionals and patients across multiple dosage-form categories. Its customer segments are healthcare practitioners (enterprise-like) and end patients (consumer), with an additional, less-developed segment in food, pharmaceutical, and cosmetic enzyme applications (papain). It is governed by a board led by Chairman and Managing Director J.V.R. Mohan Raju, alongside J. Uma, Jaison George, and independent directors Reji Abraham, Gorrela Pratheek Reddy, and Bodeddula Nagi Reddy, with Shailendra Vyas serving as Compliance Officer. Headcount is reported at 1–10 employees, and the company files standard SEBI-mandated quarterly and annual disclosures.

Financial performance has been highly variable and recently deteriorated. Quarterly reported sales have fluctuated between Rs 0 and Rs 0.38 crore, with Q3 FY26 (December 2025) showing Rs 0.38 crore in sales, an 18.42% operating margin, and Rs 0.08 crore net profit — followed by Q1 FY27 (June 2026) reporting zero revenue and a Rs 0.11 crore net loss. The company has scheduled its 34th Annual General Meeting for September 30, 2026, indicating continued operations despite revenue volatility.

Name

Hindustan Bio Sciences

Legal name

Hindustan Bio Sciences Limited

Website

https://www.hindustanbiosciences.in

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Hindustan Bio Sciences Limited is an Indian publicly listed pharmaceutical manufacturer producing finished dosage forms — injectables, tablets, capsules, syrups, drops, ointments, and pre-filled syringes — for healthcare professionals and patients, with a niche licensed nephrology drug (Recombinant Human Erythropoietin).

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIABAH

Generic Finished Dosage Form (FDF) Manufacturing

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAAAKAB

Drug Product Fill-Finish & Aseptic Manufacturing Services

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

Keywords

• Pharmaceutical manufacturing
• Finished dosage forms
• Injectable formulations
• Biopharmaceutical products
• Nephrology drugs

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Hindustan Bio Sciences generates revenue through the manufacturing and marketing of a wide range of pharmaceutical finished dosage forms including injectables, syrups, drops, tablets, capsules, and ointments. The company initially started by sourcing bulk drugs (APIs) and drug intermediates for the industry.
2. Biotechnology Products: Revenue from marketing Recombinant Human Erythropoietin, a niche nephrology drug, obtained via import license from GEAC in 2007.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Hindustan Bio Sciences Limited manufactures and markets a wide range of premium pharmaceutical finished dosage forms including dry and liquid injectables, liquid and dry syrups, Eye/Ear/Nasal drops, pre-filled syringes, non-sterile and sterile ointments, tablets, and capsules. The company also markets Recombinant Human Erythropoietin, a niche nephrology biotechnology product, under a Genetic Engineering Approval Committee (GEAC) import license obtained in 2007 after conducting clinical trials. Manufacturing is conducted at world-class facilities approved by several regulatory authorities.

Product overview

Hindustan Bio Sciences Limited (HBSL) is an integrated pharmaceutical and biotechnology company manufacturing finished dosage forms. The company operates world-class manufacturing facilities for dry and liquid injectables, liquid/dry syrups, Eye/Ear/Nasal drops, pre-filled syringes, and non-sterile/sterile ointments, tablets, and capsules. The product portfolio spans multiple pharmaceutical categories including tablets, capsules, drops, external ointments, and syrups, all approved by several regulatory authorities and trusted by healthcare professionals globally. In 2007, HBSL obtained GEAC import license for a niche nephrology product, Recombinant Human Erythropoietin, which the company markets extensively after conducting clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Tablets Pharmaceutical tablet formulations manufactured at HBSL's world-class facility, approved by regulatory authorities, for use by healthcare professionals and patients.
• Capsules Pharmaceutical capsule formulations manufactured at HBSL's world-class facility, approved by regulatory authorities, for use by healthcare professionals and patients.
• Drops (Eye/Ear/Nasal) Ophthalmic, otic, and nasal drop formulations manufactured at HBSL's world-class facility, approved by regulatory authorities.
• Externals (Ointments) Non-sterile and sterile topical ointment formulations manufactured at HBSL's world-class facility, approved by regulatory authorities.
• Syrups (Liquid/Dry) Liquid and dry syrup formulations manufactured at HBSL's world-class facility, approved by regulatory authorities.
• Dry and Liquid Injectables Sterile injectable formulations including dry and liquid formats, manufactured at world-class facilities approved by regulatory authorities, for healthcare professionals and patients.
• Pre-filled Syringes Pre-filled syringe formulations manufactured at HBSL's world-class sterile facility, approved by regulatory authorities.
• Recombinant Human Erythropoietin A nephrology biotechnology product for which HBSL obtained import license from Genetic Engineering Approval Committee (GEAC) in 2007 after conducting clinical trials. The company has been marketing this niche drug extensively since then, addressing unmet medical needs in nephrology patients.

Quantifiable outcome

• Operating profit margin of 18.42%

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Indoco Remedies: Indian generic pharmaceutical manufacturer producing tablets, capsules, injectables, and other dosage forms for domestic and export markets. Comparable to HBSL in therapeutic focus and dosage form breadth, though at meaningfully larger scale.
• Ajanta Pharma: India-based generic pharma company with a portfolio spanning tablets, capsules, injectables, and specialty products across multiple therapeutic areas. Similar business model of branded generics distributed to healthcare professionals, with international presence.
• Unichem Laboratories: Indian pharmaceutical company manufacturing finished dosage forms including tablets, capsules, and injectables with a focus on domestic and emerging market distribution. Overlaps with HBSL in generic finished dosage forms and regulatory-driven manufacturing.
• Shilpa Medicare: Indian specialty pharma manufacturer with capabilities in sterile injectables, pre-filled syringes, and biologics. Highly comparable to HBSL's injectable and biotechnology positioning, though with a larger commercial footprint.
• Bharat Parenterals Limited: Indian small/mid-cap sterile injectable manufacturer focused on parenteral dosage forms. Directly comparable to HBSL's sterile injectable and pre-filled syringe capabilities with similar regulatory-driven market access.
• Parenteral Drugs (India) Limited: Indian manufacturer of large and small volume parenterals, including sterile injectables for domestic and export markets. Closely comparable to HBSL's parenteral and aseptic manufacturing focus.

Broad incumbents

• Strides Pharma Science: Larger Indian generic pharma manufacturer with global footprint, focused on tablets, capsules, and sterile injectables. Operates in the same dosage form categories but at significantly greater scale and with broader geographic reach than HBSL.
• Cipla: One of India's largest pharmaceutical companies with a broad portfolio of generics, injectables, and specialty products across multiple therapeutic areas. Comparable product categories but with vastly greater scale, R&D budget, and global presence.

Emerging players

• TTK Healthcare: Indian pharmaceutical company with a portfolio across multiple dosage forms including pharma and consumer health products. Comparable to HBSL's diversified dosage form strategy, though with a different therapeutic focus.
• Jagsonpal Pharmaceuticals: Small-to-mid Indian pharma manufacturer of finished dosage forms including injectables and oral solids. Comparable size and business model to HBSL as a niche Indian generic manufacturer with regulatory-approved manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/hindustan-biosciences-ltd---india

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hindustan Bio Sciences